Results 111 to 120 of about 91,972 (285)
ABSTRACT The use of immune checkpoint inhibitors (ICIs) has significantly improved the efficacy of cancer therapy, but their associated immune‐related adverse events (irAEs) can severely compromise treatment safety. This review systematically summarizes the core mechanisms underlying irAEs, which include multi‐organ damage resulting from T‐cell ...
Anqi Lin+8 more
wiley +1 more source
International consensus guidance for management of myasthenia gravis
Objective: To develop formal consensus-based guidance for the management of myasthenia gravis (MG). Methods: In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 ...
D. Sanders+14 more
semanticscholar +1 more source
Quantitative Myasthenia Gravis (QMG) and Myasthenia Gravis Activities of Daily Living (MG‐ADL) scales were compared using the data from the Thymectomy Trial in Non‐Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy (MGTX) study.
Tarrant O. McPherson+7 more
semanticscholar +1 more source
Exploring the depths of IgG4: insights into autoimmunity and novel treatments
IgG4 subclass antibodies represent the rarest subclass of IgG antibodies, comprising only 3-5% of antibodies circulating in the bloodstream. These antibodies possess unique structural features, notably their ability to undergo a process known as fragment-
Selen Ünlü+12 more
doaj +1 more source
Myasthenia Gravis Related to Thymic Carcinoma: A Case Study
Myasthenia gravis and thymoma are often presented in association with ∼10% of myasthenic cases having concomitant thymoma. Thymic carcinoma is one of the rarest/aggressive human epithelial tumors and has no correlation with myasthenia gravis hitherto ...
Daniel Thomas Pereira Lopes+7 more
doaj +1 more source
Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. [PDF]
Am J Pathol. 2007 Sep;171(3):893-905. Epub 2007 Aug 3. Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status.
Adams+71 more
core +2 more sources
Teratoid Hepatoblastoma: Clinicopathologic Features and Outcomes
ABSTRACT Background Teratoid hepatoblastoma (HB) is a rare histologic subtype of the most common pediatric liver cancer. Understanding of the clinicopathologic features and outcomes of patients with this disease is currently limited. Methods Multi‐institution, retrospective chart review was conducted to compare 20 children with teratoid HB to 129 ...
Brian T. Hickner+8 more
wiley +1 more source
A Review of Psychiatric Comorbidity in Myasthenia Gravis
This study aimed to review studies focused on the affective comorbidities associated with myasthenia gravis and to determine the extent to which neuromuscular treatment modalities address non-somatic aspects of autoimmune myasthenia gravis.
Christina Law+2 more
semanticscholar +1 more source
Background and Aims An exploratory focus group study was conducted to better understand the needs of patients living with generalized myasthenia gravis (gMG).
Gabrielle Geonnotti+9 more
doaj +1 more source
Malignancies and immunoglobulin G4‐related disease
Immunoglobulin G4‐related disease (IgG4‐RD) is associated with increased cancer risk. Malignancies affect both IgG4‐RD involved organs, such as the lung, pancreas, bile duct, and prostate, and noninvolved organs, such as the gastrointestinal duct. B‐cell neoplasms constitute a proportion of the malignancies linked to this disease.
Jingna Li, Wen Zhang
wiley +1 more source